5 results
To compare the efficacy of two dose levels of erlotinib (150 mg and 300 mg) on progression-free survival (PFS) in current smokers with stage IIIB/IV NSCLC after failure of first-line platinum-based chemotherapy.
The primary objective is to determine the effect of intravenously administered rhAPC on HDM-LPS induced allergic lung inflammation.
The primary objective is to determine the effect of locally administered rhAPC on LPS-induced lung inflammation and coagulation. By using measurements on cells harvested from bronchoalveolar lavage (BAL)-fluid and in BAL-fluid supernatants, we will…
To demonstrate that treatment with drotrecogin alfa (activated) 24 mcg/kg/h administered as an intravenous infusion for 96 hours reduces 28 day all-cause mortality in adult patients with septic shock compared with placebo.
To investigate whether peri-operative dosing using a population-based pharmacokinetic model (non-linear mixed effect modelling) in hemophilia patients leads to a significant reduction in clotting factor consumption in comparison to the standard…